CODX - Co-Diagnostics Inc Stock Price, Fair Value and News

1.16USD-0.01 (-0.85%)Market Closed

Market Summary

USD1.16-0.01

Market Closed

-0.85%

CODX Stock Price

View Fullscreen

CODX RSI Chart

CODX Valuation

Market Cap

36.3M

Price/Earnings (Trailing)

-1.03

Price/Sales (Trailing)

5.32

EV/EBITDA

-0.58

Price/Free Cashflow

-1.55

CODX Price/Sales (Trailing)

CODX Profitability

Operating Margin

38.57%

EBT Margin

-559.46%

Return on Equity

-41.08%

Return on Assets

-37.07%

Free Cashflow Yield

-64.66%

CODX Fundamentals

CODX Revenue

Revenue (TTM)

6.8M

Rev. Growth (Yr)

153.67%

Rev. Growth (Qtr)

44.69%

CODX Earnings

Earnings (TTM)

-35.3M

Earnings Growth (Yr)

33%

Earnings Growth (Qtr)

-145.34%

Breaking Down CODX Revenue

Last 7 days

1.7%

Last 30 days

4.5%

Last 90 days

-6.4%

Trailing 12 Months

-14.6%

How does CODX drawdown profile look like?

CODX Financial Health

Current Ratio

10.81

CODX Investor Care

Buy Backs (1Y)

1.09%

Diluted EPS (TTM)

-1.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	27.4M	20.5M	13.7M	6.8M
2022	100.6M	78.2M	53.2M	34.2M
2021	93.0M	96.3M	104.6M	97.9M
2020	0	0	0	74.6M
2019	0	0	0	0
2018	15.7K	23.8K	31.8K	39.9K
2017	0	0	0	7.7K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Co-Diagnostics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 23, 2023	serbin richard s	acquired	-	-	30,000	-
Nov 23, 2023	egan dwight h	acquired	-	-	150,834	chief executive officer
Nov 23, 2023	nelson james b	acquired	-	-	30,000	-
Nov 23, 2023	brown brian lee	back to issuer	-45,517	1.26	-36,125	chief financial officer
Nov 23, 2023	brown brian lee	acquired	-	-	118,332	chief financial officer
Nov 23, 2023	egan dwight h	back to issuer	-58,019	1.26	-46,047	chief executive officer
Nov 23, 2023	murphy ted	acquired	-	-	30,000	-
Nov 23, 2023	durenard eugene	acquired	-	-	30,000	-
May 23, 2023	durenard eugene	acquired	-	-	18,333	-
May 23, 2023	egan dwight h	acquired	-	-	105,000	chief executive officer

Which funds bought or sold CODX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-5.87	-40,161	153,515	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-53.02	-20,000	12,000	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-570	3,360	-%
Apr 22, 2024	Raymond James Financial Services Advisors, Inc.	sold off	-100	-25,604	-	-%
Apr 18, 2024	Koss-Olinger Consulting, LLC	sold off	-100	-78,000	-	-%
Apr 17, 2024	Physician Wealth Advisors, Inc.	added	6.37	-484	39,049	0.01%
Apr 15, 2024	SMI Advisory Services, LLC	added	117	23,525	48,374	0.01%
Apr 10, 2024	Banque Cantonale Vaudoise	unchanged	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	1,080	5,320	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	480,947	2,369,110	-%

Are Funds Buying or Selling CODX?

Are funds buying CODX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CODX

No. of Funds

Unveiling Co-Diagnostics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.82%	1,781,283	SC 13G/A
Feb 09, 2023	vanguard group inc	5.76%	1,781,283	SC 13G/A
Feb 09, 2022	vanguard group inc	5.30%	1,795,057	SC 13G/A
Jul 12, 2021	blackrock inc.	1.8%	517,938	SC 13G/A
Feb 10, 2021	vanguard group inc	5.71%	1,613,884	SC 13G
Feb 02, 2021	blackrock inc.	6.8%	1,921,670	SC 13G
Jan 04, 2021	sabby management, llc	12.%	0	SC 13G/A
Feb 10, 2020	cvi investments, inc.	0%	0	SC 13G/A
Jan 28, 2020	sabby management, llc	6.63%	1,379,311	SC 13G
Jan 03, 2020	sabby management, llc	12.%	0	SC 13G/A

Recent SEC filings of Co-Diagnostics Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Mar 20, 2024	3	Insider Trading
Mar 15, 2024	8-K	Current Report
Mar 14, 2024	8-K	Current Report

Peers (Alternatives to Co-Diagnostics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	183.9B	40.1B	-6.77%	-4.63%	32.13	4.58	-8.12%	-17.45%
BDX	67.8B	19.5B	-5.19%	-11.58%	53.96	3.48	4.02%	-22.04%
ALGN	21.2B	3.9B	-13.89%	-11.01%	47.65	5.49	3.42%	23.09%
BAX	20.5B	14.8B	-5.55%	-14.80%	7.72	1.38	2.12%	209.17%
MID-CAP
ATR	9.6B	3.5B	0.34%	19.07%	30.58	2.7	6.16%	35.06%
HSIC	8.9B	12.3B	-8.26%	-15.92%	21.4	0.72	-2.44%	-22.68%
BIO	7.9B	2.7B	-22.01%	-40.57%	-12.36	2.95	-4.68%	82.43%
XRAY	6.2B	4.0B	-9.58%	-29.21%	-46.27	1.57	1.10%	85.84%
AXNX	3.4B	387.1M	-3.48%	13.50%	-213.32	8.77	30.82%	65.60%
PDCO	2.3B	6.6B	-7.88%	-6.70%	11.79	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-14.42%	-16.17%	-1.93	0.41	7.73%	-1066.14%
ANIK	383.9M	166.7M	1.93%	-0.42%	-4.64	2.3	6.67%	-456.34%
ANGO	231.9M	324.0M	-1.36%	-32.67%	-1.21	0.72	-3.19%	-337.41%
APYX	49.5M	52.3M	5.15%	-61.35%	-2.65	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-17.86%	283.33%	-0.3	0.96	5.77%	8.23%

Co-Diagnostics Inc News

Latest updates

Co-Diagnostics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	44.7%	3,555	2,457	198	800	1,401	5,094	5,023	22,699	20,401	30,101	27,358	20,025	27,145	21,819	24,040	1,549	795	41.00	62.00	36.00	11.00
Cost Of Revenue	1060.3%	2,968	256	459	502	516	768	915	3,282	2,487	3,311	2,504	3,273	4,313	5,821	5,975	482	53.00	20.00	39.00	452*	-
Gross Profit	-73.3%	587	2,201	-261	100	886	4,327	4,108	19,417	17,915	26,790	24,854	16,752	22,832	15,997	18,065	1,067	56.00	21.00	23.00	3.00	1.00
Operating Expenses	11.5%	12,413	11,137	11,733	10,050	27,007	10,862	8,255	9,593	7,606	13,160	13,063	6,417	6,803	3,959	3,357	2,149	1,679	1,671	1,389	1,257	1,825
S&GA Expenses	-20.3%	1,517	1,904	1,733	1,706	1,330	1,890	1,472	2,652	2,094	4,253	5,853	1,198	3,208	798	390	268	291	262	252	256	746
R&D Expenses	6.7%	6,179	5,789	5,981	5,014	4,739	5,037	3,890	3,771	2,182	5,893	4,669	2,217	1,113	922	750	400	381	331	313	347	375
EBITDA Margin	-44.8%	-5.41*	-3.74*	-2.26*	-1.41*	-0.51*	0.33*	0.44*	0.49*	0.47*	0.49*	0.53*	0.58*	0.57*	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91.00	-	-	15.00	45.00
Income Taxes	281.4%	3,834	-2,113	-2,238	-2,259	-3,138	-2,114	-741	1,386	2,746	2,101	2,145	1,986	-	-2,914	-	-	-	-	-	-	-
Earnings Before Taxes	-33.9%	-10,842	-8,095	-11,157	-8,015	-25,044	-3,475	-3,427	13,101	10,244	13,577	11,930	9,885	15,812	12,817	15,005	-1,065	-1,735	-1,747	-1,344	-1,368	-1,948
EBT Margin	-46.1%	-5.59*	-3.83*	-2.32*	-1.46*	-0.55*	0.31*	0.43*	0.49*	0.47*	0.49*	0.52*	0.58*	0.57*	-	-	-	-	-	-	-	-
Net Income	-145.3%	-14,676	-5,982	-8,918	-5,755	-21,905	-1,361	-2,686	11,715	7,498	11,476	9,785	7,899	12,807	15,732	15,005	-1,065	-1,735	-1,747	-1,344	-1,368	-1,948
Net Income Margin	-66.5%	-5.19*	-3.11*	-1.85*	-1.16*	-0.42*	0.28*	0.36*	0.40*	0.37*	0.40*	0.48*	0.55*	0.57*	-	-	-	-	-	-	-	-
Free Cashflow	23.2%	-5,243	-6,831	-5,693	-5,679	-4,303	888	1,147	7,409	4,757	11,343	12,182	12,130	19,489	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.3%	95.00	109	113	117	123	148	161	171	160	105	93.00	81.00	71.00	55.00	39.00	20.00	2.00	4.00	5.00	6.00	2.00
Current Assets	-12.9%	62.00	71.00	77.00	86.00	93.00	102	115	125	115	102	90.00	79.00	68.00	52.00	37.00	20.00	2.00	3.00	5.00	6.00	1.00
Cash Equivalents	45.7%	15.00	10.00	14.00	6.00	23.00	82.00	86.00	97.00	89.00	83.00	70.00	58.00	43.00	21.00	19.00	17.00	1.00	3.00	4.00	5.00	1.00
Inventory	-63.2%	2.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	2.00	3.00	4.00	6.00	8.00	11.00	10.00	1.00	0.00	0.00	0.00	0.00	0.00
Net PPE	8.1%	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	-	-	-	-	-	-	15.00	15.00	15.00	15.00	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	1.2%	9.00	9.00	9.00	6.00	9.00	13.00	16.00	23.00	26.00	5.00	6.00	5.00	5.00	2.00	3.00	1.00	0.00	0.00	1.00	1.00	3.00
Current Liabilities	12.7%	6.00	5.00	5.00	4.00	4.00	6.00	7.00	13.00	13.00	4.00	5.00	4.00	4.00	2.00	3.00	1.00	0.00	0.00	0.00	0.00	2.00
Shareholder's Equity	-13.5%	86.00	99.00	103	111	115	135	144	148	134	100	87.00	76.00	67.00	53.00	36.00	19.00	2.00	3.00	5.00	6.00	-
Retained Earnings	-76.1%	5.00	19.00	25.00	34.00	40.00	62.00	63.00	66.00	54.00	47.00	35.00	25.00	18.00	5.00	-11.03	-26.03	-24.97	-23.15	-21.41	-20.06	-18.69
Additional Paid-In Capital	1.9%	97.00	95.00	93.00	91.00	88.00	86.00	84.00	82.00	80.00	53.00	52.00	51.00	49.00	48.00	47.00	45.00	27.00	26.00	26.00	26.00	18.00
Shares Outstanding	2.0%	31.00	31.00	31.00	31.00	31.00	32.00	32.00	34.00	34.00	29.00	29.00	29.00	29.00	-	-	-	-	-	-	-	-
Float	-	-	-	33.00	-	-	-	187	-	-	-	229	-	-	-	485	-	-	-	10.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	27.5%	-4,778	-6,594	-5,209	-5,499	-4,009	1,118	1,654	7,806	4,878	11,509	12,424	12,270	19,958	8,556	987	-1,335	-1,612	-1,215	-1,328	-1,368	-960
Share Based Compensation	-15.9%	1,826	2,172	2,170	2,169	2,404	2,230	1,533	1,375	1,658	1,411	927	1,513	571	1,238	302	433	276	276	126	88.00	762
Cashflow From Investing	203.3%	9,615	3,170	13,237	-10,632	-53,306	4,739	-10,459	859	1,071	870	-234	2,393	1,246	-6,150	-669	-250	-38.78	-96.69	-227	-72.00	-242
Cashflow From Financing	4.0%	-159	-166	-555	-482	-1,217	-10,394	-2,571	150	-	5.00	296	149	543	275	863	18,062	-	-	-	5,903	-22.86
Buy Backs	-4.0%	160	166	556	482	-	10,395	2,599	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CODX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Total revenue	$ 6,812,038	$ 34,218,209
Cost of revenue	4,184,949	5,481,093
Gross profit	2,627,089	28,737,116
Operating expenses
Sales and marketing	6,860,815	7,344,628
General and administrative	14,279,441	14,262,963
Research and development	22,962,593	17,438,098
Depreciation and amortization	1,230,474	1,282,718
Goodwill impairment charges		15,388,546
Total operating expenses	45,333,323	55,716,953
Loss from operations	(42,706,234)	(26,979,837)
Other income, net
Interest income	1,161,913	704,045
Realized gain on investments	2,243,059
Loss on disposition of assets	(2,578)	(138,117)
Gain on remeasurement of acquisition contingencies	1,092,581	7,899,644
Gain (loss) on equity method investment in joint venture	100,703	(332,969)
Total other income, net	4,595,678	8,132,603
Loss before income taxes	(38,110,556)	(18,847,234)
Income tax benefit	(2,777,691)	(4,608,985)
Net loss	(35,332,865)	(14,238,249)
Other comprehensive loss
Change in net unrealized gains on marketable securities, net of tax	(146,440)	293,140
Total other comprehensive income (loss)	(146,440)	293,140
Comprehensive loss	$ (35,479,305)	$ (13,945,109)
Loss per common share:
Basic	$ (1.20)	$ (0.45)
Diluted	$ (1.20)	$ (0.45)
Weighted average shares outstanding:
Basic	29,346,599	31,479,028
Diluted	29,346,599	31,479,028
Product Revenue [Member]
Total revenue	$ 991,473	$ 34,218,209
Grant Revenue [Member]
Total revenue	$ 5,820,565

CODX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 14,916,878	$ 22,973,803
Marketable investment securities	43,631,510	58,289,066
Accounts receivable, net	303,926	3,453,723
Inventory, net	1,664,725	5,310,473
Income taxes receivable	26,955	1,870,419
Prepaid expenses and other current assets	1,597,114	761,187
Note receivable		75,000
Total current assets	62,141,108	92,733,671
Property and equipment, net	3,035,729	2,539,483
Operating lease right-of-use asset	2,966,774	372,115
Intangible assets, net	26,403,667	26,768,333
Investment in joint venture	773,382	672,679
Total assets	95,320,660	123,086,281
Current liabilities
Accounts payable	1,482,109	952,296
Accrued expenses	2,172,959	934,447
Operating lease liability, current	838,387	297,209
Contingent consideration liabilities, current	891,666	1,689,471
Deferred revenue	362,449
Total current liabilities	5,747,570	3,873,423
Long-term liabilities
Income taxes payable	659,186	1,181,284
Deferred tax liability		2,417,987
Operating lease liability	2,152,180	50,708
Contingent consideration liabilities	748,109	1,042,885
Total long-term liabilities	3,559,475	4,692,864
Total liabilities	9,307,045	8,566,287
Stockholders’ equity
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,108,346 shares issued and 31,259,668 shares outstanding as of December 31, 2023 and 34,754,265 shares issued and 30,872,607 shares outstanding as of December 31, 2022	36,108	34,754
Treasury stock, at cost; 4,848,678 and 3,881,658 shares held as of December 31, 2023 and December 31, 2022, respectively	(15,575,795)	(14,211,866)
Additional paid-in capital	96,808,436	88,472,935
Accumulated other comprehensive income	146,700	293,140
Accumulated earnings	4,598,166	39,931,031
Total stockholders’ equity	86,013,615	114,519,994
Total liabilities and stockholders’ equity	$ 95,320,660	$ 123,086,281

About Co-Diagnostics Inc

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CEO	Mr. Dwight H. Egan
WEBSITE	codiagnostics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	145

Co-Diagnostics Inc Frequently Asked Questions

What is the ticker symbol for Co-Diagnostics Inc? What does CODX stand for in stocks?

CODX is the stock ticker symbol of Co-Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Co-Diagnostics Inc (CODX)?

As of Tue Apr 30 2024, market cap of Co-Diagnostics Inc is 36.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CODX stock?

You can check CODX's fair value in chart for subscribers.

What is the fair value of CODX stock?

You can check CODX's fair value in chart for subscribers. The fair value of Co-Diagnostics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Co-Diagnostics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CODX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Co-Diagnostics Inc a good stock to buy?

The fair value guage provides a quick view whether CODX is over valued or under valued. Whether Co-Diagnostics Inc is cheap or expensive depends on the assumptions which impact Co-Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CODX.

What is Co-Diagnostics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, CODX's PE ratio (Price to Earnings) is -1.04 and Price to Sales (PS) ratio is 5.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CODX PE ratio will change depending on the future growth rate expectations of investors.